Eli Lilly led a landmark strategic anchor investment in clinical-stage radiopharmaceutical developer Aktis Oncology as the company raised $318 million in its initial public offering. Lilly’s commitment, part of a broader collaboration valued at up to $1.2 billion, underscores its growing focus on targeted alpha-emitter therapies for solid tumors. Under the agreement, Lilly will partner on the development of Aktis’s lead program, AKY-1189, an actinium-225–labeled agent targeting Nectin-4, as well as second pipeline candidate AKY-2519 against B7-H3. This collaboration builds on Lilly’s oncology expansion strategy, adding a novel modality to its immuno-oncology and targeted therapy franchises while sharing development costs and potential milestone and royalty payments tied to clinical and commercial milestones.

Eli Lilly has entered into a multi-year collaboration with AI innovator Chai Discovery to deploy Chai’s advanced antibody-design platform for multiple biologic targets. Under the agreement, Lilly will fund the creation of a bespoke AI model trained exclusively on Lilly’s proprietary data sets, accelerating early-stage candidate generation. The deal follows an initial evaluation period in which Chai-designed molecules demonstrated double-digit experimental hit rates in zero-shot antibody screens. The collaboration includes undisclosed upfront payments, dataset licensing fees, and development-stage success milestones, aligning incentives to rapidly translate in silico designs into lead therapeutic candidates and potentially shorten Lilly’s discovery timelines by several months per program.

In its recently reported TOGETHER-PsA Phase 3b trial, Eli Lilly demonstrated that combining its dual-agonist weight-management therapy Zepbound (tirzepatide) with Taltz (ixekizumab) for psoriatic arthritis patients with obesity led to a 31.7% rate of ACR50 responses at week 24, compared with 0.8% for Taltz alone—a 64% relative improvement. The combination also drove a mean weight reduction of 12.3% versus 1.1% in the monotherapy arm. Reported adverse events were predominantly mild to moderate gastrointestinal symptoms consistent with the known safety profiles of both agents. Lilly plans to present detailed data at an upcoming rheumatology congress and pursue label expansion discussions based on these results.